Drugmaker Hikma reports higher annual profit

Feb 22 (Reuters) - British drugmaker Hikma Pharmaceuticals HIK.L, on Thursday, beat profit expectations for the year, helped by strong performance of its branded and generics businesses.

The company reported a 19% rise in core operating profit for the year ended on Dec. 31 to $707 million. It expects a profit of $660 million to $700 million for this year.

Analysts on average expected core profit for 2023 to be about $689 million, while they forecast 2024 numbers to be about $680 million, according to a company compiled consensus.

(Reporting by Radhika Anilkumar in Bengaluru; Editing by Savio D'Souza)


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.